lung cancer gene and literature database Home
Cancer metastasis database

Annotation category 5

Literatures

Literature evidence

Links to all GeneRIF Items

6240

PubMed (Gene Name)

Literature evidence

12687015 (RRM1)

overexpression of RRM1 in human and mouse lung cancer cell lines induced PTEN expression, reduced phosphorylation of focal adhesion kinase (FAK), suppressed migration, invasion, and metastasis formation, and increased survival in an animal model.

15172981 (RRM1)

The level of RRM1 may affect gemcitabine response in non-small cell lung cancer. Furthermore, RRM1 may serve as a biomarker for gemcitabine response.

18414411 (RRM1)

Ribonucleotide reductase subunit M1(RRM1) mRNA expression in lung adenocarcinoma is associated with clinical outcome of docetaxel/gemcitabine therapy.

19304340 (RRM1)

genetic polymorphisms is associated with sensitivity to platin-based chemotherapy in non-small cell lung cancer patients

20211060 (RRM1)

Compared with their parental cells, the expressions of CDA, RRM1, PTEN and ERCC1 increase in human gemcitabine-resistant non-small cell lung cancer cell lines.

20226083 (RRM1)

RRM1 single nucleotide polymorphism is not associated with non-small cell lung cancer patients after gemcitabine-based chemotherapy.

20467918 (RRM1)

ERCC1, RRM1 and BRCA1 are promising predictive and prognostic biomarkers in advanced non-small cell lung cancer.

21370501 (RRM1)

RRM1 has a role in response to gemcitabine plus platinum therapy in advanced non-small-cell lung cancer

21642870 (RRM1)

Single-nucleotide polymorphisms in RRM1 gene is associated with treatment response in non-small cell lung cancer.

23086647 (RRM1)

The expression of RRMI and ERCC1 genes in tumor tissues and RRM1 in peripheral blood lymphocytes is closely correlated with the response to chemotherapy and prognosis of patients with advanced non-small cell lung cancer.

23803067 (RRM1)

High RRM1 expression is associated with non-small cell lung cancer.

24155212 (RRM1)

low expression of RRM1 and RRM2 could be used to predict the treatment response to platinum-based chemotherapy and survival in non-small cell lung cancer

24591771 (RRM1)

RRM1 gene expression may contribute to chemotherapy sensitivity and may be an indicator of survival in nonsmall cell lung cancer patients treated with gemcitabine plus cisplatin.

26323924 (RRM1)

The genotype of ribonucleotidereductase M1 -269C > A is associated with the response to platinum-based chemotherapy and as a prognostic biomarker in advanced nonsmall cell lung cancer

26542178 (RRM1)

study finds that ERCC1 and RRM1 are not independent prognostic factors of recurrence in stage I non-small cell lung cancer patients

26637889 (RRM1)

A possible predictive impact of ribonucleotide-reductase subunit-1 (RRM1) on vinorelbine efficacy in non-small cell lung cancer (NSCLC) has been previously reported.

26650486 (RRM1)

Presence of rare AA (-37C>A) and CC (-524C>T) genotypes of the RRM1 may be favorable predictive factors for chemotherapy with platinum compounds and gemcitabine in non-small cell lung cancer patients.

26718430 (RRM1)

A significant association has been found between RRM1 rs12806698 (-269C>A) RRM1 genotype and the risk for developing non-small cell lung cancer.

27587543 (RRM1)

three SNPs (corepressor interacting with RBPJ 1 (CIR1) rs13009079T>C, ribonucleotide reductase M1 (RRM1) rs1465952T>C and solute carrier family 38, member 4 (SLC38A4) rs2429467C>T), may play a role in the pathogenesis of lung cancer

27908619 (RRM1)

RRM1 single nucleotide polymorphism is associated with Non-Small-Cell lung cancer.